Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 4

Sponsor Class

OTHER 13NIH 4INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Precancerous Conditions 1Colorectal Neoplasms 1Adenomatous Polyps 1Adenomatous Polyposis Coli 1

Interventions

Cyclophosphamide 178Radiotherapy 147Paclitaxel 128Carboplatin 124Bevacizumab 123Cisplatin 119Doxorubicin 111Fluorouracil 107Etoposide 102Filgrastim 99Vincristine 88Leucovorin 82Bortezomib 80Gemcitabine 76aldesleukin 74Sorafenib 70Cytarabine 70Taxes 69fludarabine phosphate 67Irinotecan 66Docetaxel 64Oxaliplatin 60sargramostim 58Sirolimus 58temsirolimus 56Erlotinib Hydrochloride 56Methotrexate 55Rituximab 54Vorinostat 52Radiation 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × NIH × Eflornithine × Clear all
NCT00033371 2020-09-29

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

National Cancer Institute (NCI)

Phase 2 Completed
205 enrolled 16 charts
Gastrointestinal

Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT00983580 2019-09-04

Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
107 enrolled 10 charts

Adenomatous Polyps

NCT00118365 2015-01-22

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

National Cancer Institute (NCI)

Phase 3 Completed
375 enrolled 27 charts
Other neoplasm

Precancerous Conditions

NCT00003814 2013-12-18

Eflornithine in Treating Patients With Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Completed
450 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡